Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line immunotherapy-chemotherapy with or without stereotactic body radiation for metastatic non-small cell lung cancer
2021-002453-28Phase 2Terminated
- Sponsor
- Santa Maria Nuova
- Start
- Oct 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab, pemetrexed, carboplatin, cisplatin and paclitaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Santa Maria Nuova. Primary endpoint: Objective response rate. Started Oct 2021; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-002453-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002453-28.